Inflammatix, Inc.
Biotechnology ResearchCalifornia, United States51-200 Employees
Inflammatix is a biotechnology research company based in Sunnyvale, California, focused on emergency and critical care medicine by analyzing the body’s immune response to inform decisions for patients with suspected acute infection or sepsis. Its FDA-cleared TriVerity test is a rapid blood assay that uses AI analysis of immune mRNA expression to deliver three results in about 30 minutes: the likelihood of bacterial infection, the likelihood of viral infection, and the risk of near-term clinical deterioration. This approach supports risk stratification and clinical assessment in the emergency department, helping clinicians determine which patients may require closer monitoring or inpatient care versus lower-acuity pathways. The insights generated from immune response data are intended to support real-time clinical decision-making while aligning with health-system priorities such as operational efficiency and antimicrobial stewardship. The company serves clinicians and health systems facing acute infectious presentations in emergency settings, seeking to reduce diagnostic uncertainty at the point of care. It operates within the biotechnology diagnostics space, positioned at the intersection of molecular diagnostics and critical-care decision support. Inflammatix recently partnered with the University of Nebraska Medical Center to support rapid hantavirus outbreak response using TriVerity, illustrating a current application of its platform to public health emergencies.
1-888-653-2347 
support@leadiq.com 
